Pioglitazone decreases plasma angiotensin II concentration in type 2 diabetes

Journal of Atherosclerosis and Thrombosis

Volumn 17, Issue 6, 2010, Pages 651-657

  Saiki, Atsuhito ^a   Ohira, Masahiro ^a   Endo, Kei ^a   Koide, Nobukiyo ^a   Oyama, Tomokazu ^a   Murano, Takeyoshi ^a   Miyashita, Yoh ^a   Shirai, Kohji ^a  

^a TOHO UNIVERSITY   (Japan)

Author keywords

Angiotensin II; Insulin resistance; Lipoprotein lipase; Pioglitazone

Indexed keywords

ANGIOTENSIN II; CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; INSULIN; LPL PROTEIN, HUMAN; RAS PROTEIN;

ADIPOCYTE; ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CELL DIFFERENTIATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; AGED; BIOSYNTHESIS; BLOOD; DIABETES MELLITUS, TYPE 2; METABOLISM; MIDDLE AGED;

ADIPOCYTES; AGED; ANGIOTENSIN II; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPOPROTEIN LIPASE; MALE; MIDDLE AGED; RAS PROTEINS; THIAZOLIDINEDIONES;

EID: 77954719344     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.4002     Document Type: Article

References (31)

1. Alpert MA, Govindarajan G, Del Rosario ML, Reisin E: The role of the renin-angiotensin system in the pathophysiology, prevention, and treatment of renal impairment in patients with the cardiometabolic syndrome or itscomponents. J Cardiometab Syndr, 2009; 4: 57-62
2. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM: Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes, 2002; 51: 1699-1707
3. Karlsson C, Lindell K, Ottosson M, Sjostrom L, Carlsson B, Carlsson LM: Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab, 1998; 83: 3925-3929
4. Saiki A, Ohira M, Endo K, Koide N, Oyama T, Murano T, Watanabe H, Miyashita Y, Shirai K: Circulating angiotensin II is associated with body fat accumulation and insulin resistance in obese subjects with type 2 diabetes mellitus. Metabolism, 2009; 58: 708-713
5. Sharma AM, Staels B: Review: Peroxisome proliferator-activated receptor gamma and adipose tissue-understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab, 2007; 92: 386-395
6. Gillies PS, Dunn CJ: Pioglitazone. Drugs, 2000; 60: 333-343; discussion 344-335
7. Koide N, Oyama T, Miyashita Y, Shirai K: Effects of calorie- restricted low-carbohydrate diet on glucose and lipid metabolism in Otsuka Long Evans Tokushima Fatty rats. J Atheroscler Thromb, 2007; 14: 253-260
8. Teramoto T, Yamada N, Shirai K, Saito Y: Effects of pioglitazone hydrochloride on Japanese patients with type 2 diabetes mellitus. J Atheroscler Thromb, 2007; 14: 86-93
9. Saiki A, Murano T, Watanabe F, Oyama T, Miyashita Y, Shirai K: Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes. J Atheroscler Thromb, 2005; 12: 163-168
10. Mori Y, Itoh Y, Obata T, Tajima N: Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes. Endocrine, 2006; 29: 143-148
11. Shirai K, Itoh Y, Sasaki H, Totsuka M, Murano T, Watanabe H, Miyashita Y: The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum. Diabetes Res Clin Pract, 1999; 46: 35-41
12. Saiki A, Oyama T, Endo K, Ebisuno M, Ohira M, Koide N, Murano T, Miyashita Y, Shirai K: Preheparin serum lipoprotein lipase mass might be a biomarker of metabolic syndrome. Diabetes Res Clin Pract, 2007; 76: 93-101
13. Kobayashi J, Saito K, Fukamachi I, Taira K, Takahashi K, Bujo H, Saito Y: Pre-heparin plasma lipoprotein lipase mass: correlation with intra-abdominal visceral fat accumulation. Horm Metab Res, 2001; 33: 412-416
14. Hanyu O, Miida T, Kosuge K, Ito T, Soda S, Hirayama S, Wardaningsih E, Fueki Y, Obayashi K, Aizawa Y: Preheparin lipoprotein lipase mass is a practical marker of insulin resistance in ambulatory type 2 diabetic patients treated with oral hypoglycemic agents. Clin Chim Acta, 2007; 384: 118-123
15. Hanyu O, Miida T, Obayashi K, Ikarashi T, Soda S, Kaneko S, Hirayama S, Suzuki K, Nakamura Y, Yamatani K, Aizawa Y: Lipoprotein lipase (LPL) mass in preheparin serum reflects insulin sensitivity. Atherosclerosis, 2004; 174: 385-390
16. Miyashita Y, Ito Y, Hasiguchi S, Totsuka M, Aoki A, Kurokawa M, Tomioka H, Shirai K: Effect of temocapril hydrochloride on serum lipid levels in patients with hypertensive type 2 diabetes mellitus. J Atheroscler Thromb, 2001; 8: 25-29
17. Hitsumoto T, Takahashi M, Iizuka T, Shirai K: Effect of the angiotensin II receptor antagonist telmisartan on lipoprotein lipase mass in preheparin serum. J Atheroscler Thromb, 2008; 15: 138-145
18. Saiki A, Koide N, Watanabe F, Murano T, Miyashita Y, Shirai K: Suppression of lipoprotein lipase expression in 3T3-L1 cells by inhibition of adipogenic differentiation through activation of the renin-angiotensin system. Metabolism, 2008; 57: 1093-1100
19. Harte A, McTernan P, Chetty R, Coppack S, Katz J, Smith S, Kumar S: Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone. Circulation, 2005; 111: 1954-1961
20. Kobayashi H, Shimamoto K, Moriguchi O: [Radioimmunoassay of human plasma angiotensin II (author's transl)]. Horumon To Rinsho, 1979; 27: 665-669
21. Kobayashi J, Hashimoto H, Fukamachi I, Tashiro J, Shirai K, Saito Y, Yoshida S: Lipoprotein lipase mass and activity in severe hypertriglyceridemia. Clin Chim Acta, 1993; 216: 113-123
22. Nagashima K, Lopez C, Donovan D, Ngai C, Fontanez N, Bensadoun A, Fruchart-Najib J, Holleran S, Cohn JS, Ramakrishnan R, Ginsberg HN: Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest, 2005; 115: 1323-1332
23. Janke J, Schupp M, Engeli S, Gorzelniak K, Boschmann M, Sauma L, Nystrom FH, Jordan J, Luft FC, Sharma AM: Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator- activated receptor-gamma activation. J Hypertens, 2006; 24: 1809-1816
24. Reid IA, Morris BJ, Ganong WF: The renin-angiotensin system. Annu Rev Physiol, 1978; 40: 377-410
25. Navar LG, Nishiyama A: Why are angiotensin concentrations so high in the kidney? Curr Opin Nephrol Hypertens, 2004; 13: 107-115
26. Franco M, Martinez F, Quiroz Y, Galicia O, Bautista R, Johnson RJ, Rodriguez-Iturbe B: Renal angiotensin II concentration and interstitial infiltration of immune cells are correlated with blood pressure levels in salt-sensitive hypertension. Am J Physiol Regul Integr Comp Physiol, 2007; 293: R251-256
27. Tornvall P, Olivecrona G, Karpe F, Hamsten A, Olivecrona T: Lipoprotein lipase mass and activity in plasma and their increase after heparin are separate parameters with different relations to plasma lipoproteins. Arterioscler Thromb Vasc Biol, 1995; 15: 1086-1093
28. Watanabe H, Miyashita Y, Murano T, Hiroh Y, Itoh Y, Shirai K: Preheparin serum lipoprotein lipase mass level: the effects of age, gender, and types of hyperlipidemias. Atherosclerosis, 1999; 145: 45-50
29. Wallinder L, Peterson J, Olivecrona T, Bengtsson-Olivecrona G: Hepatic and extrahepatic uptake of intravenously injected lipoprotein lipase. Biochim Biophys Acta, 1984; 795: 513-524
30. Kennefick TM, Anderson S: Role of angiotensin II in diabetic nephropathy. Semin Nephrol, 1997; 17: 441-447
31. Nicola W, Sidhom G, El Khyat Z, Ibrahim S, Salah A, El Sayed A: Plasma angiotensin II, renin activity and serum angiotensin-converting enzyme activity in non-insulin dependent diabetes mellitus patients with diabetic nephropathy. Endocr J, 2001; 48: 25-31